Antibodies to Factor VII

Factor VII, human

Antibody Host Catalogue No. Size Product Insert
Purified IgG Sheep SAFVII-IG 10 mg Factor VII (FVII, F7) - polyconal antibody - purified IgG - Affinity Bioloigcals
Affinity purified IgG Sheep SAFVII-AP 0.5 mg Factor VII (FVII, F7) - polyconal antibody - affinity purified IgG - Affinity Bioloigcals
Peroxidase conjugated IgG Sheep SAFVII-HRP 0.2 mg Factor VII (FVII, F7) - polyconal antibody - peroxidase conjugate IgG - Affinity Bioloigcals
Affinity purified, FITC conjugated IgG Sheep SAFVII-APFTC 0.1 mg Factor VII (FVII, F7) - polyclonal antibody - sheep - affinity purified FITC conjugated IgG
Affinity purified, biotinylated IgG Sheep SAFVII-APBIO 0.1 mg Factor VII (FVII, F7) - polyclonal antibody - sheep - affinity purified biotinylated conjugated IgG
Matched Pair Antibodies for EIA FVII-EIA 5 plates Factor VII (FVII, F7) - matched pair antibodies for ELISA antigen - Affinity Bioloigcals
Analyte Specific Reagents
– Affinity purified IgG SAFVII-AP-ASR 0.5 mg Factor VII (FVII, F7) - polyconal antibody - affinity purified IgG - (ASR)
– Peroxidase conjugated IgG SAFVII-HRP-ASR 0.2 mg Factor VII (FVII, F7) - polyconal antibody - peroxidase conjugate IgG -ASR
  SAFVII-APFTC – Flow Cytometry application

Description of Factor VII

Factor VII (FVII, also known as Stable Factor and Proconvertin) is a vitamin K-dependent glycoprotein produced in the liver. Plasma concentration of FVII is normally ~0.5 μg/ml (10 nM) in plasma. A deficiency of FVII is associated with bleeding in a clinical pattern similar to haemophilia, but is inherited as an autosomal recessive trait. The deficiency can be characterized by a quantitative (low activity and low antigen) or a qualitative (low activity and normal antigen) defect in FVII function. In its zymogen form FVII is a single chain molecule of ~50 kDa. It contains two EGF-like domains and an amino-terminal domain containing 10 γ-carboxyglutamic acid (Gla) residues. These Gla residues allow FVII to bind divalent metal ions and participate in calcium-dependent binding interactions. FVII and activated FVII (FVIIa) bind to tissue factor exposed at the site of vascular injury. FIXa, FXa or FVIIa rapidly activate tissue factor-bound FVII to FVIIa in the presence of calcium and phospholipid. Thrombin and FXIIa are able to activate FVII in the fluid phase in the absence of cofactors. The activation of the single chain zymogen FVII occurs by proteolysis after residue Arg152, resulting in a two-chain active serine protease consisting of a 30 kDa heavy chain and a 18 kDa light chain. In complex with tissue factor, phospholipid and calcium, FVIIa is able to activate F.X and F.IX. Free FVIIa in plasma is remarkably stable, but the activity of FVIIa/TF complex is regulated by Tissue Factor Pathway Inhibitor (TFPI) in the presence of F.Xa, and also by Antithrombin (ATIII) in the presence of heparin1-3.

References and Reviews
  1. Rao LVM, Bajaj SP, Rapaport SI; Activation of Human Factor VII During Clotting in Vitro; Blood 65, pp 218-226, 1985.
  2. Lawson, JH, Butenas S, Ribarik N, Mann KG; Complex-dependent Inhibition of Factor VIIa by Antithrombin III and Heparin; JBC 268 pp 767-770, 1993.
  3. Nemerson Y, in Hemostasis and Thrombosis, 3rd Edition, eds. RW Colman, J Hirsh, VJ Marder and EW Salzman, pp. 81-93, J.B. Lippincott Co., Philadelphia PA, USA, 1994.